Entero Healthcare Solutions Limited (ENTERO)
₹1,585.00 +0.25% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Entero Healthcare's revenue was ₹1,940 Cr (+38.2% year on year, +1.6% on the previous quarter), and net profit ₹52.1 Cr (+72.2% year on year); the operating margin was 5.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹1,940 | +38.2% | +1.6% |
| Operating profit | ₹97.0 | +93.7% | +12.8% |
| Net profit | ₹52.1 | +72.2% | +15.7% |
| EPS (₹) | 8.77 | +37.2% | +36.2% |
| Operating margin | 5.0% | — | — |
ENTERO delivery percentage and bulk deals
NSE end-of-day data for
On Fri, 16 Oct 2026, 51.27% of the ENTERO shares traded on NSE were taken to delivery, against the stock's own 20-session average of 53.22%. That is close to its usual level. Volume was 0.4 times its average, well below normal. 3 bulk or block deals were reported in ENTERO in the last 60 days: ₹236 Cr bought and ₹236 Cr sold.
Delivery in the last 5 sessions: 58.5% · 52.4% · 42.7% · 49.3% · 51.3%
| Date | Side | Counterparty | Value | Price | Quantity | Type |
|---|---|---|---|---|---|---|
| 18 Sep | Buy | Hdfc Mutual Fund | ₹235.60 Cr | ₹1,695.00 | 1,390,000 | Block |
| 18 Sep | Sell | Prasid Uno Family Trust | ₹207.10 Cr | ₹1,695.00 | 1,221,820 | Block |
| 18 Sep | Sell | Prasid Unofamily Trust | ₹28.51 Cr | ₹1,695.00 | 168,180 | Block |
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Entero Healthcare Solutions Limited announced that its officials will participate in a group investor conference on September 29, 2026, starting at 02:00 P.M. The virtual meeting is being organized by Arihant Capital Markets Ltd. The company confirmed that interactions will be restricted to publicly available information and no unpublished price-sensitive information (UPSI) will be shared. This represents a standard procedural disclosure under SEBI LODR Regulation 30.
- Virtual group investor meeting scheduled for September 29, 2026, from 02:00 P.M. onwards
- Investor conference is organized by Arihant Capital Markets Ltd.
- Interaction will rely strictly on publicly available information with no UPSI discussed
Entero Healthcare Solutions Limited reported that the GST Authority (Uttar Pradesh) imposed a monetary penalty of ₹12,91,728 on its subsidiary, ACE Cardiopathy Solutions Private Limited. The penalty was issued on September 11, 2026, due to the non-generation of an E-Invoice. The amount has been paid under protest to release a detained vehicle and mitigate operational disruptions, with ACE Cardiopathy intending to pursue a refund under GST law. Given Entero's TTM revenue of ₹5,528 crore, the financial impact is negligible (<0.01% of revenue).
- GST Authority (Uttar Pradesh) levied a penalty of ₹12,91,728 on subsidiary ACE Cardiopathy Solutions Private Limited
- Penalty imposed for non-generation of E-Invoice, received on September 11, 2026
- Amount paid under protest to secure immediate release of vehicle and avoid demurrage
- ACE Cardiopathy plans to pursue recovery/refund through remedies available under GST law
Entero Healthcare Solutions Limited has scheduled institutional investor interactions organized by Elara Capital on September 2, 2026, starting at 3:00 PM IST in Mumbai. The interactions will include 1x1 and group meetings in physical mode. The company confirmed that discussions will focus strictly on publicly available information with no unpublished price-sensitive information (UPSI) shared.
- Investor conference scheduled for September 02, 2026, from 03:00 P.M. onwards
- Interaction type includes 1x1 and group meetings held physically in Mumbai
- Conference is organized by Elara Capital
- Company confirmed no unpublished price-sensitive information (UPSI) will be discussed
Entero Healthcare Solutions Limited announced that the tenure of Mr. Rajesh Shashikant Dalal (DIN: 03504969) as Non-Executive Independent Director concluded on August 24, 2026. Consequently, Mr. Dalal ceases to serve as the Chairperson of the Nomination and Remuneration Committee and Stakeholders Relationship Committee, as well as a member of the Audit Committee. The change is a standard scheduled completion of tenure and does not reflect any operational disruption. The company will need to reconstitute the relevant board committees in due course.
- Tenure of Non-Executive Independent Director Rajesh Shashikant Dalal concluded at the close of business on August 24, 2026
- Ceases to be Chairperson of the Nomination and Remuneration Committee and Stakeholders Relationship Committee
- Steps down as a member of the Audit Committee effective August 24, 2026
- Filing follows prior company intimation letters dated July 13, 2026, and August 07, 2026
Entero Healthcare Solutions Limited concluded its 8th Annual General Meeting on August 19, 2026, where all 7 agenda items were approved by shareholders. Resolutions included adoption of FY26 financial statements (99.9996% in favour) and approval of executive remuneration for MD & CEO Prabhat Agrawal (93.58% in favour) and WTD & COO Prem Sethi (93.95% in favour). Independent directors Sujesh Vasudevan and Sandhya Gadkari Sharma were also re-appointed for a second term with over 94.3% support.
- Adoption of FY26 consolidated financial statements passed with 99.9996% votes in favour (3,32,86,807 votes)
- Payment of remuneration to MD & CEO Prabhat Agrawal approved with 93.58% favour (2,73,79,142 votes) against 6.42% dissent
- Remuneration for Whole Time Director & COO Prem Sethi passed with 93.95% approval
- Re-appointment and remuneration for Independent Directors Sujesh Vasudevan and Sandhya Gadkari Sharma approved with >94.3% voting support
Entero Healthcare Solutions reported a 38.2% YoY revenue growth to ₹1,940 Cr in Q1 FY27, led by 17.8% organic growth and 20.4% inorganic contribution from prior acquisitions. Operating EBITDA surged 94% YoY with margins expanding 143 bps to 5.0%, achieving the management's full-year FY27 margin target in the first quarter itself. PAT increased 72% YoY to ₹52 Cr (PAT attributable to owners stood at ₹38 Cr), aided by scale-led procurement efficiencies and higher-margin MedTech expansion. Management reaffirmed its FY27 guidance of ~23% consolidated revenue growth and expects MedTech revenue to cross ₹1,000 Cr organically.
- Consolidated revenue climbed 38.2% YoY (40.0% like-for-like) to ₹1,940 Cr in Q1 FY27.
- EBITDA rose 94% YoY to achieve a 5.0% margin, up 143 bps YoY, meeting the full-year target early.
- Net profit after tax grew 72% YoY to ₹52 Cr, with minority interest accounting for ₹14 Cr.
- Working capital cycle improved to 61 days from 66 days YoY; ROCE expanded to 21.1% from 11.5% YoY.
- MedTech revenue is projected to exceed ₹1,000 Cr organically during FY27.
Entero Healthcare Solutions has released the audio recording of its earnings conference call for the quarter ended June 30, 2026. This follows the company's recent financial results disclosure and provides management's detailed commentary on performance. Investors can access the recording via the company's website, with a written transcript to follow. The company currently operates with a TTM revenue of ₹4,992 Cr and a P/E of 64.9.
- Audio recording for the quarter ended June 30, 2026, is now publicly available
- Follows previous regulatory intimations dated August 4 and August 5, 2026
- Company maintains a TTM revenue base of ₹4,992 Cr as per latest annual figures
- Management previously guided for 30% revenue growth for FY26 through organic and inorganic routes
Entero Healthcare reported a strong start to FY27 with consolidated revenue reaching Rs 1,940.5 Cr, a 38% YoY increase. Operational efficiency improved significantly as EBITDA grew 94% to Rs 97 Cr, with margins expanding 143 bps to 5.0%. Return ratios showed marked improvement, with ROCE nearly doubling to 21.1% and ROE reaching 20.4%. The company maintained its growth momentum with organic growth of 17.8%, outperforming the Indian Pharmaceutical Market (IPM) growth of 12%.
- Consolidated revenue grew 38% YoY to Rs 1,940.5 Cr, contributing ~39% of the previous TTM revenue in a single quarter
- EBITDA margins expanded by 143 bps YoY to reach 5.0%, driven by higher-margin MedTech and trade generics
- Return on Capital Employed (ROCE) improved significantly to 21.1% from 11.5% in Q1 FY26
- Organic revenue growth of 17.8% outperformed the Indian Pharmaceutical Market (IPM) growth of 12%
- Net Working Capital (NWC) days improved to 61 days from 66 days in the previous year
Entero Healthcare reported a weak set of standalone results for Q1 FY27, with net profit dropping 50.3% YoY to ₹3.46 Cr from ₹6.96 Cr. While standalone revenue from operations grew 4.9% YoY to ₹83.27 Cr, profitability was hit by a 120% surge in finance costs (₹5.74 Cr vs ₹2.60 Cr) and a decline in other income. The company continues its strategy of supporting subsidiaries, subscribing to Optionally Convertible Debentures (OCDs) in four entities during the quarter. Board committees were also reconstituted following the retirement of an independent director.
- Standalone Revenue from operations increased 4.9% YoY to ₹83.27 Cr.
- Standalone Net Profit declined 50.3% YoY to ₹3.46 Cr from ₹6.96 Cr in the year-ago period.
- Finance costs surged by 120.7% YoY to ₹5.74 Cr, impacting the bottom line.
- Subscribed to OCDs in 4 subsidiaries including Avenues Pharma and Sri Parshva Pharma.
- Allotted 12,135 equity shares under ESOP at a premium of ₹794 per share.
Entero Healthcare Solutions has issued a revised intimation for its Q1 FY27 earnings call, providing an updated meeting link for the session. The call is scheduled for August 10, 2026, at 12:00 PM IST to discuss financial results for the quarter ended June 30, 2026. This follows a fiscal year (FY26) where the company reported a TTM revenue of Rs 4,992 Cr and a PAT of Rs 113 Cr. The revision is purely administrative, with no changes to the date, time, or management participants.
- Earnings call scheduled for August 10, 2026, at 12:00 Noon IST
- Discussion focuses on Unaudited Financial Results for the quarter ended June 30, 2026
- Revision pertains solely to the meeting link provided in the August 04, 2026, letter
- Management participants include the MD & CEO, Whole Time Director & COO, and Group CFO
Entero Healthcare Solutions has scheduled its earnings conference call for August 10, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026. The management team, including the CEO and CFO, will address investors following a fiscal year (FY26) that saw revenue reach ₹4,992 Cr with a PAT of ₹113 Cr. This call is critical for assessing the company's progress toward its 30% revenue growth guidance and the integration of its recent MedTech acquisitions.
- Earnings conference call scheduled for August 10, 2026, at 12:00 Noon IST.
- Discussion will cover unaudited financial results for the quarter ended June 30, 2026.
- Management participants include MD & CEO Prabhat Agrawal and Group CFO Dr. Balakrishnan Natesan.
- Company reported a TTM revenue of ₹4,992 Cr and an operating profit margin of 3.7% as of FY26.
- Investors will look for updates on the ₹237 Cr IPO proceeds allocated for inorganic growth.
Entero Healthcare Solutions has announced the incorporation of a new step-down subsidiary, Qurovia Lifesciences Private Limited, effective July 25, 2026. The entity is a wholly-owned subsidiary of R S M Pharma Private Limited, which is itself a wholly-owned subsidiary of Entero. Qurovia has been established with an authorized share capital of ₹1.5 crore, though the initial subscription is a nominal ₹1 lakh. This move aligns with Entero's stated strategy of aggressive expansion in pharmaceutical distribution and MedTech services.
- Incorporated on July 25, 2026, with the certificate received on July 31, 2026
- Authorized share capital of ₹1,50,00,000 comprising 15,00,000 equity shares
- Initial cash subscription of ₹1,00,000 for 10,000 equity shares
- Wholly owned by R S M Pharma Private Limited, a 100% subsidiary of Entero
Entero Healthcare has issued an updated Annual Report for FY 2025-26 to correct an inadvertent error in Note 52 of the Consolidated Financial Statements. The report confirms a strong financial performance for the year, with revenue reaching ₹6,591 crore, a 29.3% increase over the previous year. EBITDA grew by 55% to ₹266 crore, while operating cash flow turned positive at ₹96 crore. The company is aggressively expanding into the MedTech segment, which is projected to contribute over ₹1,000 crore in annualized revenue by FY27.
- FY26 Revenue reported at ₹6,591 crore, representing 29.3% year-on-year growth
- EBITDA increased by 55% to ₹266 crore, with margins improving to 4.0%
- Operating cash flow reached a milestone of ₹96 crore in FY26
- Network expanded to 136 warehouses serving over 105,300 retail pharmacy customers
- MedTech business expected to exceed ₹1,000 crore in annualized revenue during FY27
Entero Healthcare has released its FY25-26 Annual Report, reporting a 29.3% revenue growth to ₹6,591 crore, significantly outperforming the broader pharmaceutical market. EBITDA grew 55% YoY to ₹266 crore, with margins expanding from 3.4% to 4.0% due to operating leverage and a better product mix. A key milestone was achieved with positive operating cash flow of ₹96 crore, while ROCE improved to 14.6%. The company is now targeting over ₹1,000 crore in annualized revenue from its MedTech segment in FY27.
- FY26 Revenue reached ₹6,591 crore, representing 29.3% reported growth and 31.5% like-for-like growth
- EBITDA increased by 55% to ₹266 crore, with EBITDA margins improving 60 bps to 4.0%
- Achieved ₹96 crore in operating cash flow, a significant milestone for the company
- MedTech business expected to contribute >₹1,000 crore of annualized revenue in FY27
- Network expanded to 136 warehouses covering 523 districts and 105,300+ retail pharmacy customers
Entero Healthcare has filed its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, covering consolidated operations across 48 subsidiaries. The company maintains a significant distribution footprint with 137 warehouses across 21 states, supporting its TTM revenue of ₹4,992 Cr. The report highlights a workforce of 4,943 employees and a 100% domestic sourcing model, with 7.92% of inputs coming from MSMEs. Notably, the company reported zero data breaches and zero consumer complaints regarding data privacy or service delivery for the period.
- Operates a network of 137 warehouses and offices across 21 Indian states as of March 31, 2026
- Total workforce stands at 4,943 employees, including 4,671 permanent staff
- 100% of revenue is derived from the distribution and marketing of healthcare products
- Sourced 7.92% of input materials from MSMEs, up slightly from 7.73% in the previous year
- Reported zero instances of data breaches and zero consumer complaints for FY 2025-26
Financial Performance
Revenue Growth by Segment
Total revenue for Q2 FY26 reached INR 1,571 Cr, representing a 20.8% YoY growth. On a like-to-like basis, adjusted for contracts on a net margin basis, revenue growth was 23.4% YoY. Organic revenue growth stood at 13.4% YoY, which is 1.8x the Indian Pharmaceutical Market (IPM) growth rate of 7.3%. The MedTech segment is projected to cross INR 1,000 Cr in annualized revenue following the integration of recent acquisitions.
Geographic Revenue Split
Not specifically disclosed by region, but the company operates a massive portfolio across 100-plus warehouses nationwide to service various geographies.
Profitability Margins
Gross margin for Q2 FY26 improved to 10.2%, up 84 bps YoY and 29 bps QoQ. PAT margin expanded to 2.3% in Q2 FY26 from 2.0% in Q2 FY25. Profit After Tax (PAT) grew 41% YoY to INR 37 Cr. These improvements are driven by a shift toward higher-value categories like MedTech and trade generics.
EBITDA Margin
EBITDA margin reached 4.0% in Q2 FY26, an improvement of 69 bps YoY and 38 bps QoQ. EBITDA for the quarter was INR 62 Cr, up 46% YoY. The company expects a further proforma impact of 50 to 75 bps on EBITDA margins once all MedTech acquisitions are fully integrated.
Capital Expenditure
The company utilized INR 193 Cr of IPO proceeds for inorganic growth through acquisitions as of March 31, 2025, with INR 44 Cr remaining for this purpose. Acquisitions are funded through a mix of internal accruals, cash balance, and some debt addition.
Credit Rating & Borrowing
The company utilized INR 142.5 Cr of IPO proceeds for the full repayment/prepayment of certain borrowings. Interest was paid back during the reversal of specific territory transactions, though specific interest rate percentages are not disclosed.
Operational Drivers
Raw Materials
As a healthcare distributor, 'raw materials' consist of pharmaceutical products, medical devices, diagnostic consumables, and equipment (cardiology and orthopedic devices).
Import Sources
Not disclosed in available documents; however, the company services products across 100+ warehouses in India.
Key Suppliers
The company distributes for various pharmaceutical and MedTech manufacturers; specific supplier names are not listed, but they carry a 'massive product portfolio'.
Capacity Expansion
Expansion is focused on warehouse reach and segment depth. The company closed 5 acquisitions between July and October 2025 to expand into the MedTech segment.
Raw Material Costs
Gross profit stood at INR 161 Cr (+32% YoY). Procurement efficiency and operational cost optimization contributed to an 84 bps YoY improvement in gross margins.
Manufacturing Efficiency
Not applicable as a distributor; however, operational efficiency is measured by the improvement in RoCE, which rose to 13.8% in Q2 FY26 from 11.0% YoY.
Logistics & Distribution
The role of the distributor in MedTech is more value-added (commercial role), allowing for higher margin pools compared to standard distribution.
Strategic Growth
Expected Growth Rate
30%
Growth Strategy
The 30% revenue growth guidance for FY26 will be achieved through a combination of organic growth (currently 13.4%) and aggressive inorganic expansion. The company is fast-tracking the closure of acquisitions in the MedTech and trade generics segments to bridge the 2.5% gap seen in H1 FY26 growth (27.8% like-to-like vs 30% target).
Products & Services
Pharmaceutical products, trade generics, diagnostic consumables, diagnostic equipment, cardiology medical devices, and orthopedic medical devices.
Brand Portfolio
Entero Healthcare Solutions; the company also operates through various acquired subsidiaries in the MedTech and distribution space.
New Products/Services
Expansion into MedTech (consumables and equipment) and trade generics, which are higher growth and margin accretive.
Market Expansion
Significant expansion in the MedTech segment through 5 new acquisitions closed in H2 2025. The company aims to scale its digital and technology infrastructure to improve healthcare access across India.
Market Share & Ranking
The company's organic growth of 13.4% is 1.8x the Indian Pharmaceutical Market (IPM) growth of 7.3%, indicating significant market share gains.
Strategic Alliances
The company utilizes acquisitions rather than JVs, targeting single-digit EV/EBITDA multiples for all new deals.
External Factors
Industry Trends
The MedTech industry is high-growth and offers higher margin pools for distributors who take on commercial roles. The industry is shifting toward organized distribution and digital infrastructure to improve supply chain efficiency.
Competitive Landscape
The company competes in a fragmented distribution market but is consolidating its position through acquisitions at attractive single-digit multiples.
Competitive Moat
Moat is built on a massive scale (100+ warehouses), a diversified product portfolio (Pharma + MedTech), and a data-driven approach to inventory and credit, which reduced working capital days by 6 days YoY.
Macro Economic Sensitivity
Sensitive to the growth of the Indian Pharmaceutical Market (IPM), which grew at 7.3% during the period.
Consumer Behavior
Chemists reportedly reduced procurement between August 15 and September 15, 2025, due to GST changes, yet Entero maintained 20.8% revenue growth through effective transition management.
Geopolitical Risks
Not specifically mentioned, though the company focuses on the domestic Indian healthcare market.
Regulatory & Governance
Industry Regulations
Operations are subject to the Companies Act 2013, Ind AS, and GST regulations. The company successfully navigated the GST transition in September 2025 across its 100+ warehouses.
Taxation Policy Impact
Direct taxes paid (net of refund) amounted to INR 25.9 Cr in H1 FY26 compared to INR 14.1 Cr in H1 FY25.
Legal Contingencies
The Secretarial Audit Report for FY ended March 31, 2025, reported that the company has adequate systems to ensure compliance with applicable laws and that all board decisions were carried unanimously with no dissenting views.
Risk Analysis
Key Uncertainties
The primary uncertainty is the timing and integration of inorganic deals; a delay in closures resulted in a 2.5% gap relative to the 30% growth guidance in H1 FY26.
Geographic Concentration Risk
Not disclosed, but the company operates 100+ warehouses, suggesting broad domestic diversification.
Third Party Dependencies
The company is dependent on pharmaceutical and MedTech manufacturers for supply, though its 'massive portfolio' across 100+ warehouses suggests a diversified vendor base.
Technology Obsolescence Risk
The company is actively investing in digital, data, and technology infrastructure to mitigate the risk of falling behind in supply chain automation.
Credit & Counterparty Risk
The company has implemented ongoing initiatives around credit monitoring and enhanced collection discipline, successfully reducing working capital days to 63.
